Dr Christina O’Neill is the CEO of VascVersa. She has extensive experience in the vascular biology field, having worked in this area as a postdoctoral scientist at Queen’s University Belfast for over a decade. In addition, Dr O’Neill has pioneered work in isolating the vascular stem cells that underpins ANGICYTE™ technology and has been directly involved in optimising protocols for their production, expansion and characterisation. She has a keen interest in commercialisation pathways for cell therapies. 

Dr O’Neill successfully led the team through the NxNW ICURe programme and was instrumental in winning several IUK grant awards. Dr O'Neill is central to the company and is both a highly accomplished scientist and business leader, having completed several entrepreneurial and leadership programmes.